By Drug Target Review2025-09-02T09:00:52
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2023-04-12T15:28:08
Sponsored by nanoComposix
2023-05-10T11:18:16
Sponsored by Revvity
2023-05-31T15:16:10
Sponsored by Bio-Techne
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2023-09-27T13:56:39
Sponsored by Euretos
Site powered by Webvision Cloud